[MBN] Miracell Selected as One of the “Top 1000 Innovative Companies in the Nation”
Miracell selected as one of the “1000 Innovative Companies” Stem cell company Miracell has been selected as one of the government’s “1,000 Leading Innovative Companies.” Miracell (CEO Shin Hyun-soon) announced on the 1st that it was selected for the third round of the “1,000 Leading Innovative Companies” program, announced by the Financial Services Commission, based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. The “1,000 Leading Innovative Companies” program, comprised of nine ministries including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Oceans and Fisheries, selects leading innovative companies by industry and provides them with exceptional financial support to foster them as future core companies. Launched on July 30, 2020,the program was approved at the 12th meeting of the Central Economic Response Headquarters. Starting with 32 companies in the first round, 247 were selected in the second round, and 321 companies were selected this time. The Financial Services Commission plans to select 1,000+ representative innovative companies from each industry by 2022. Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical devices, and innovative pharmaceuticals categories, based on selection criteria established by the Ministry of Health and Welfare. Launched in 2009 with the introduction of Harvard University’s cell extraction technology, Miracell successfully developed a “Minimally Manipulated Stem Cell Isolation and Amplification Source Technology” in 2017. The Ministry of SMEs and Startups selected this technology for a small business commercialization technology development project. Based on this technology, Miracell successfully developed and domestically produced SmartPReP2, a kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported globally, and SMART M-CELL2, a replacement kit. Test results from Seoul National University Bundang Hospital showed that its performance was comparable to or even superior to SmartPReP2. Smart Mcell 2 is a device that extracts large quantities of automatically separated stem cells from bone marrow blood extracted from the body through centrifugation. It is currently used in major hospitals both domestically and internationally. CEO Shin Hyun-soon stated, “Being selected as a National Representative Innovative Company is very significant. It opens up new avenues for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.” CEO Shin continued, “Stem cell therapy involves extracting bone marrow blood from the patient, concentrating it through centrifugation, extracting a large quantity of stem cells, and then reinjecting them into the body. Because old cells regenerate into healthy ones, it is highly effective in improving bodily functions.” Recognized as an innovative technology, Smart Mcell 2 is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be isolated and extracted in one session,within an hour, and cell viability rates reach a remarkable 80-98%.Its automated system features a closed, air-tight system that prevents cell deformation. Smart Mcell 2 is equipped with special LEDs to enhance cell activity, converting the existing analog system to digital, and even features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices. Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, our biological pharmaceutical manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. We also have secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, and 22 patent applications for cell extraction technology.
[Edaily] Miracell Selected as One of the Top 1000 Innovative Companies in the Health and Diagnostics Sector
Miracell selected as one of the nation’s top 1000 innovative companies in the health and diagnostics sector. ▶ View original article [Edaily Reporter Lee Soon-yong] Stem cell company Miracell has been selected as one of the government’s “1000 Innovative Companies.” Miracell (CEO Shin Hyun-soon) announced on the 1st that it has been selected for the third round of the “1000 Innovative Companies,” a list announced by the Financial Services Commission based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. The “1000 Innovative Companies” list is a support system for nine ministries, including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Oceans and Fisheries. It selects leading innovative companies by industry and provides them with exceptional financial support to foster them as future core companies. The program was launched on July 30, 2020, with a resolution passed at the 12th Central Economic Response Headquarters meeting. Starting with 32 companies selected in the first round, 247 were selected in the second round, and 321 companies were selected this time. The Financial Services Commission plans to select a total of 1,000+α representative innovative companies in each industry by 2022. Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical device, and innovative pharmaceutical sectors, based on selection criteria established by the Ministry of Health and Welfare. Miracell is a stem cell company launched in 2009 with the introduction of cell extraction technology from Harvard University. In 2017, it successfully developed a “minimally manipulated stem cell isolation and amplification source technology,” and the Ministry of SMEs and Startups selected this technology as a technology development project for commercialization by SMEs. In particular, based on this technology, the company successfully developed and domestically produced SMART M-CELL2, a replacement for the SmartPReP2 kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported worldwide. Test results at Seoul National University Bundang Hospital showed that its performance was comparable to or even superior to that of SMART M-CELL2. SMART M-CELL2 is a device that extracts large quantities of automatically separated stem cells by concentrating bone marrow blood extracted from the body through centrifugation. It is currently used in major hospitals both domestically and internationally. CEO Shin Hyun-soon stated, “Being selected as a national innovative company is very significant. It has opened up new avenues for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.” He continued, “Stem cell therapy is a treatment that extracts bone marrow blood from the patient, concentrates it through centrifugation, extracts a large amount of stem cells, and then injects them back into the body.” He explained, “Because old cells are regenerated into healthy ones, the treatment is highly effective in improving the body’s functions.” Smart Mcell 2, recognized as an innovative technology, is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be separated and extracted in less than an hour, with a cell viability rate of 80-98%.Its unique feature is its automated, closed system, which prevents contact with air and prevents cell deformation.Smart Mcell 2 is equipped with special LEDs to enhance cell activity, transitioning from analog to digital. It also features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices. Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, its biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. Furthermore, Miracell has secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, as well as 22 patent applications for cell extraction technology.
Miracell Selected as One of the “1000 National Innovative Companies in the Health and Diagnostics Sector”
Miracell Selected as One of the “1000 National Innovative Companies in the Health and Diagnostics Sector” Stem cell specialist Miracell has been selected as one of the government’s “1000 Innovative Companies.” According to the company on the 1st, Miracell was selected for the third round of the “1000 Innovative Companies,” announced by the Financial Services Commission, based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. This time, 321 companies were selected. Miracell was selected as one of the “Health and Diagnostic Innovation Companies” in the health technology, medical device, and innovative pharmaceutical categories, according to the Ministry of Health and Welfare’s selection criteria. Launched in 2009 as a stem cell specialist company with the introduction of Harvard University’s cell extraction technology,the company successfully developed a “minimally manipulated stem cell isolation and amplification source technology” in 2017. The Ministry of SMEs and Startups selected this technology as a technology development project for commercialization by small and medium-sized enterprises.In 2018, Miracell successfully developed and domestically produced the Smart Mcell 2 kit, a replacement for the Smart Prep kit developed by the Harvard Medical School’s Immunology Research Institute and exported worldwide. CEO Shin Hyun-soon stated, “Being selected as a national innovative company is very significant. This opens up a new avenue for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.” Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, its biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. Reporter Kim Si-young kimsy@asiatoday.co.kr
Miracell Selected as One of the “1000 National Innovative Companies in the Health and Diagnostics Sector”
Miracell selected as one of the “1000 National Innovative Companies in the Health and Diagnostics Sector” A stem cell specialist dedicated to research and development Stem cell specialist Miracell has been selected as one of the government’s “1,000 Leading Innovative Companies.” Miracell (CEO Shin Hyun-soon) announced on the 1st that it was selected for the third round of the “1,000 Leading Innovative Companies,” a program announced by the Financial Services Commission based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare. The “1,000 Leading Innovative Companies” program, launched on July 30, 2020, was approved at the 12th meeting of the Central Disaster and Safety Countermeasures Headquarters. The program selects leading innovative companies by industry and provides them with exceptional financial support to foster them as future core companies. Starting with 32 companies in the first round, 247 were selected in the second round, and 321 companies have been selected this time. The Financial Services Commission plans to select 1,000+ representative innovative companies from each industry by 2022. Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical device, and innovative pharmaceutical sectors, based on selection criteria established by the Ministry of Health and Welfare. Launched in 2009 with the introduction of Harvard University’s cell extraction technology, Miracell successfully developed a “minimally manipulated stem cell isolation and amplification source technology” in 2017. The Ministry of SMEs and Startups selected this technology for a small business commercialization technology development project. Based on this technology, Miracell successfully localized and independently developed the SMART M-CELL2 kit, a replacement for the SmartPReP2 kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported globally. Test results at Seoul National University Bundang Hospital showed that Miracell’s performance was comparable to or even superior to that of SmartPReP.Smart Mcell 2 is a device that extracts large quantities of automatically separated stem cells from bone marrow blood extracted from the body through centrifugation. It is currently used in major hospitals both domestically and internationally. CEO Shin Hyun-soon (pictured) stated, “Being selected as a National Representative Innovative Company is very significant. It opens up new avenues for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.” He continued, “Stem cell therapy involves extracting bone marrow blood from the patient, concentrating it through centrifugation, extracting a large quantity of stem cells, and then reinjecting them into the body. Because old cells regenerate into healthy ones, it is highly effective in improving bodily functions in the affected area.” Recognized as an innovative technology, Smart Mcell 2 is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be isolated and extracted in less than an hour, with a cell viability rate of 80-98%. Its automated system features a closed, air-tight system that prevents cell deformation. Smart Mcell 2 features a special LED to enhance cell activity, transitioning from analog to digital. It also features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices. Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, our biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. Furthermore, we have secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, and 22 patent applications for cell extraction technology.
Miracell Hosts the 2021 Selfia Global Platform Academy
[Miracell Hosts ‘2021 Selfia Global Platform Academy’]On the 27th, he will present a lecture on ‘Facial Scaffolds and Stem Cell Lifting.’ [Edaily Reporter Lee Soon-yong] Stem cell specialist Miracell (CEO Shin Hyun-soon) held the “2021 CGP Academy” on the 27th under the theme of “Facial Scaffolds and Stem Cell Lifting.” Mr. Eun-soo Park, a plastic surgeon (Director of the Department of Plastic Surgery at Soonchunhyang University Bucheon Hospital), served as the lecturer. Following a theoretical lecture on facial scaffolds and stem cell lifting, the event included a 60-minute live skin lifting session using blood-derived stem cells, hands-on training, and a Q&A session. Following the popular topic of “Hair Loss Treatment Using Stem Cells” in the previous session, which drew significant attention, this session on “Facial Scaffolds and Stem Cell Lifting” also received positive reviews. Stem cell thread lifting involves inserting cosmetic PDO threads, taking into account skin elasticity and muscle mass, followed by stem cell transplantation. The academy’s attendees also responded enthusiastically to the demonstration that stem cells strengthen the elasticity of muscles and skin layers, and thereby rejuvenate aged skin. The Cellpia Global Platform Academy (CGP) was established in 2019 with the goal of sharing technology and knowledge related to stem cell regenerative medicine, contributing not only to specialized stem cell treatments and research, but also to the treatment of various diseases. The CGP Academy fosters a network of hospitals and clinics, including Cellpia Clinic, a leading stem cell education institution, and members of the Global Platform Membership, to discuss stem cell medical technologies. The Cellpia Global Platform is a systematic, professional medical membership that provides education, technology transfer, medical equipment setup, and marketing services to domestic and international hospitals to ensure safer stem cell regenerative medicine treatments. CEO Shin Hyun-soon stated, “Through the Cellpia Global Platform Academy, cutting-edge medical devices and medical technologies are being actively shared.” “We will actively lead the growth of regenerative medicine technologies to specialize in safe stem cell treatments.” ▶View original article: https://www.edaily.co.kr/news/readnewsId=03116006628988240&mediaCodeNo=257&OutLnkChk=Y
[Sejongno Government Forum] Incurable Degenerative Diseases and Stem Cell Therapy
[Introducing the Sejong-ro Government Forum Regular Members] Intractable Degenerative Diseases and Stem Cell Therapy Reporter Lee Ho-su As we enter the age of centenarians, stem cell therapy is an essential element in extending life, regenerating aged cells and treating intractable degenerative diseases. Stem cells are cells with the potential to develop into various cell types that make up the body’s tissues. Stem cells play a role in the regeneration of damaged tissues and cells. They possess the ability to self-renew indefinitely,allowing them to differentiate into various tissues and organs,and contributing directly or indirectly to the well-being of the body. Shin Hyun-soon, CEO of Miracell and current chair of the Stem Cell Committee at the Sejongno Government Forum, launched the stem cell business in 1986 as a medical industry initiative. By 2009, Miracell has grown into a specialized stem cell company that respects life and promotes a healthy lifestyle. Since then, Miracell has been at the forefront of developing and upgrading safe and effective stem cell treatments through collaborative clinical research with medical professionals from around the world, professional societies, and university hospitals in Korea. In particular, Miracell hosted an international conference in March 2011 in Korea, a landlocked area for stem cell therapy. Approximately 700 medical doctors from Harvard and other universities and home and abroad were invited to present theoretical and practical demonstrations on various medical specialties. Furthermore, Miracell was the first in Korea to introduce bone marrow stem cell, mesenchymal stem cell, and hematopoietic stem cell therapies. Approved by the Ministry of Food and Drug Safety and the Ministry of Health and Welfare, the company offers treatments for myocardial infarction, critical limb ischemia, cartilage regeneration, bone fusion, hair loss, plastic surgery, and sexual medicine. These treatments are currently being performed at over 500 hospitals and clinics nationwide. Stem cells are cells that continuously divide and possess the ability to find and regenerate damaged tissues and organs, making them highly effective in disease treatment and prevention. Therefore, Cellpia Clinic, a stem cell specialist, offers a unique treatment that extracts and concentrates stem cell growth factors without culturing them. This method involves extracting stem cells from blood vessels, isolating and extracting only those cells that can be activated, and then reintroducing them into the body. This process not only enhances the immune system but also regenerates damaged tissue, significantly improving symptoms. In the era of COVID-19, autoimmunity has become crucial for fighting viruses. NK cell testing can detect autoimmunity and potentially prevent disease. ▶See the original article at http://www.peoplekorea.press/View.aspx?No=1534026
Miracell Hosts “Selfia Global Platform” Academy
【Health and Welfare News】Miracell (CEO Shin Hyun-soon) recently held the “2021 Selfia Global Platform Academy (CGP Academy)” (Photo) The CGP Academy, held at Miracell’s headquarters on the 23rd of last month, focused on “hair loss.” Participants included the CEO of Selfia Clinic and medical institutions affiliated with the Selfia Global Platform (CGP). Miracell’s CGP Academy provided a platform for participants to gain a deeper understanding of stem cells and share techniques for non-surgical stem cell hair loss treatments. Unlike previous sessions, participants were able to experience the treatment firsthand after the live training, which reportedly resonated with many. Miracell CEO Shin Hyun-soon stated, “Through the academy, I was able to reaffirm the direction of improving the quality of life through world-class medical technology and stem cells. Based on the positive feedback from this seminar, we plan to continue the academy in March with a different theme.” Original News > http://www.whosaeng.com/124531
International St. Mary’s Hospital is recruiting participants for a clinical trial of a stem cell treatment for plantar fasciitis.
Professor Shim Dong-woo [Financial News] As summer approaches, rising humidity leads to the wearing of shoes with thin and hard soles. Excessive walking or prolonged standing due to improper footwear can increase the risk of plantar fasciitis. Plantar fasciitis is a common foot condition, characterized by inflammation of the broad fascia that extends from the heel bone to the toes. It is known to occur twice as often in women as in men. Pain often extends to the inner heel and the inner side of the foot, and is typically worst when patients take their first steps in the morning. Plantar fasciitis requires conservative treatment for at least six months. If symptoms persist beyond this period, surgery may be considered. However, careful consideration is required, as it can lead to complications such as nerve damage. Professor Shim Dong-woo of International St. Mary’s Hospital announced on the 19th that he is conducting a clinical trial to demonstrate the effectiveness of stem cell injection therapy, a non-surgical treatment, in patients with plantar fasciitis. Professor Shim explained, “Stem cell therapy has been suggested as a treatment option for osteochondral injuries of the talus. While clinical data are still limited, Ambrosi et al. reported significant clinical improvement in four patients with osteochondral injuries of the talus after administering autologous adipose-derived stem cells.” He added, “In this study, we aim to report the differences in treatment outcomes associated with stem cell therapy in patients with refractory plantar fasciitis, whose symptoms persist despite appropriate conservative treatment.” The cutting-edge, convergent medical devices and medical supplies used in this clinical study are supplied by Miracell. Autologous bone marrow-derived stem cells are extracted and used for treatment to regenerate the plantar fascia and reduce inflammation in patients with plantar fasciitis injuries. This medical device has been approved by the Ministry of Food and Drug Safety for the treatment of cartilage injuries. Approximately 60ml of bone marrow is collected from the patient. Using medical supplies and a cutting-edge convergence system provided by Miracell, advanced cells are obtained through minimal manipulation. These cells, including healthy stem cells and immune cells, are then injected directly into the fascia. Pain and inflammation gradually decrease 15 days after the procedure, leading to healing. Patients with plantar fasciitis who wish to participate in the study can contact Miracell (mira1@mira119.com). Pompom@fnnews.com, Reporter Jeong Myeong-jin Original article link: https://www.fnnews.com/news/202005190918029425
Immunity against viruses… Expected to be strengthened with cutting-edge stem cells.
[Health Digest = Reporter Choi Min-young] While the nationwide COVID-19 outbreak stemming from the Itaewon club outbreak has once again raised concerns, statistics indicate that the likelihood of further spread has significantly decreased. However, the Korea Centers for Disease Control and Prevention (KCDC) and experts have stated that the end of COVID-19 remains uncertain, and a second wave of the pandemic in the fall is a concern. Biotechnology companies both domestically and internationally are focused on developing vaccines and antibodies, but they predict it will take months, if not more than a year, for treatments to become widely available. COVID-19 has thrown the world into a state of unpredictable turmoil, and it continues to unfold. Even as treatments are being developed, we cannot afford to let our guard down. Therefore, preserving and strengthening our immune systems until the pandemic is over is crucial. Reports of cases of COVID-19 patients being treated with stem cells, a cutting-edge cell type, are fueling growing interest in stem cells. On March 18th, the British daily Daily Mail reported that a joint study by the American stem cell company BHI and Dr. Wu Dongcheng of Wuhan, China, successfully treated nine elderly patients with severe COVID-19 by administering intravenous stem cell injections. Furthermore, on March 2nd, the Hong Kong-based South China Morning Post (SCMP) reported that a research team led by Professor Hu Min of Kunming University in Yunnan Province, China, published a paper reporting that a 65-year-old woman with severe COVID-19 in China tested negative for the virus and showed improvement after receiving stem cell treatment. In response, Miracell Bio Research Institute (CEO Shin Hyun-soon), a stem cell specialist company, stated, “Based on the latest research findings, stem cells extracted from a patient’s own bone marrow or blood have the ability to reduce inflammation and find, regenerate, and repair damaged tissue.” “Stem cells can help suppress excessive inflammatory responses by activating tissue regeneration through communication with immune cells in damaged areas of the body and also controlling inflammatory responses,” he explained. The medical team at Cellpia, a domestic stem cell specialty clinic, stated, “The human body possesses natural killer (NK) cells, innate immune cells that can kill viruses and abnormal cells that invade the body without antibodies. NK cell activity is crucial for survival against COVID-19.” “Given the cases of increased NK cell activity following intravenous stem cell administration, it can be said that stem cells play a crucial role in treating viral diseases and enhancing our immune system.” While large-scale clinical trials of stem cell therapy have not yet been reported, active research is underway both domestically and internationally, as it is being applied to treat intractable and degenerative diseases. Reporter Choi Min-young kunkang1983@naver.com Original article link: http://www.ikunkang.com/news/articleView.html?idxno=31410
Cutting-edge stem cell technology is being used to treat diabetic complications.
[Edaily Reporter Park Cheol-geun] With the number of diabetic patients rapidly increasing, efforts are being made to develop medical technologies to treat diabetic complications. Injuries, particularly those at the toes, the farthest point from the heart, are often neglected. This neglect poses a particularly dangerous risk for patients with diabetic critical limb ischemia. Diabetic critical limb ischemia is primarily caused by vascular problems, which hinder wound healing, enlarge wounds, and make recovery difficult. In some cases, this can lead to amputation or the use of prosthetics. For those without health insurance, the high cost of treatment can be a significant concern. Consequently, the government is conducting clinical trials with subsidized funds to reduce the burden on patients while maximizing the effectiveness of advanced cell therapy. The cost of the procedure is approximately 5.5 million won, with government funding of 1 million won for the general public and 1.56 million won for the lower-income bracket. A representative from stem cell specialist Miracell explained, “Advanced cell stem cells (SmartPrep) possess self-renewal and differentiation capabilities, allowing them to differentiate into any tissue in the body, including the lungs, liver, kidneys, and skin.” They added, “They are effective in treating vascular diseases by reducing inflammation, regenerating damaged tissue and blood vessels, and improving blood circulation.” Notably, Harvard Medical School in the United States published a paper on the treatment of diabetic critical limb ischemia patients by injecting them into the muscles surrounding the leg arteries using a total advanced cell system containing stem cells extracted through an advanced cell system, CD34+ cells that treat vascular nephrocytes, and growth factors. This has provided hope to patients suffering from this condition worldwide. A company representative explained, “We are treating 100 diabetic critical limb ischemia patients at a limited number of hospitals, including Professor Park Soon-chul of the Department of Vascular and Transplant Surgery at Seoul St. Mary’s Hospital, Professor Lee Dong-yeon of the Department of Orthopedic Surgery at Seoul National University Hospital, and Professor Park Eun-soo of the Department of Plastic Surgery at Soonchunhyang University Bucheon Hospital.” Meanwhile, patients with diabetic critical limb ischemia who wish to participate in this trial can submit a simple application to Miracell headquarters by filling out their name and contact information. Original article link: https://www.edaily.co.kr/news/read?newsId=02591206625798112&mediaCodeNo=257